Short answer
KESTRA MEDICAL TECHNOLOGIES, LTD. (KMTS) filed its Q4 2025 10-Q quarterly report on Dec 11, 2025 for the quarter ended Oct 31, 2025. Quarterly revenue was $23M with net income of −$33M.
Q4 2025 key financials · XBRL
- Revenue
- $23M
- +16.5% QoQ
- Net income
- −$33M
- −26.9% QoQ
- Operating margin
- -140.7%
- Gross margin
- 50.6%
- EPS (diluted)
- −$0.64
- −28.0% QoQ
Source: XBRL data from the KESTRA MEDICAL TECHNOLOGIES, LTD. (KMTS) Q4 2025 10-Q on SEC EDGAR. USD.
KESTRA MEDICAL TECHNOLOGIES, LTD. Q4 2025 10-Q analysis
AI summary of MD&A and risk factor updates
Risk Factors
- Risk Factors section not provided; filing text contains only forward-looking-risk references
- Regulatory risk: Maintaining ASSURE WCD approvals and securing clearances for new markets
- Operational risk: Scaling manufacturing while securing timely component supplies
- Market risk: Reimbursement availability and ASSURE WCD market acceptance
- Financial risk: Increased expenses associated with public-company status
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other KESTRA MEDICAL TECHNOLOGIES, LTD. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.